Business Wire

SamanTree Medical Achieves FDA Clearance for Histolog® Scanner, Ushering in a New Era of Tissue Imaging in the U.S.

13.9.2024 09:00:00 EEST | Business Wire | Press release

Share

SamanTree Medical, a leader in innovative surgical imaging solutions, today announced that it has received FDA 510(k) clearance of its Histolog® Scanner for imaging of the internal microstructure of tissues including, but not limited to, the identification of cells, vessels and their organization or architecture. This groundbreaking Swiss made device is designed to provide real-time, highresolution imaging of fresh tissue surfaces, offering surgeons and pathologists this information for excised tissue.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240912995435/en/

The Histolog Scanner in use for rapid visualization of fresh tissue microstructures. (Photo: SamanTree Medical)

The Histolog® Scanner enables real-time, ultra-fast confocal microscopy, allowing for the immediate imaging of resected tissues. This advancement aims to enable physicians to improve their efficiency.

“We are thrilled to introduce the Histolog® Scanner to the U.S. market,” said Dr. Charles Carignan, Executive Chairman of SamanTree Medical. “This FDA clearance is a significant milestone for the company. The ability of the Histolog® Scanner to produce real-time imaging of the internal microstructure of tissues provides surgeons and pathologists with immediate, actionable information.”

Prof. Dr. Alex Mottrie, Head of the Urological Department OLV Hospital, Aalst, Belgium and CEO of ORSI Academy, Ghent, Belgium, commented on the impact of this new technology: “The Histolog® Scanner represents cutting-edge technology in imaging of freshly excised tissue. Its ability to provide high-resolution, real-time images allows us to make more informed decisions.”

Prof. Dr. Ari D. Brooks, Director of Endocrine and Oncologic Surgery, Pennsylvania Hospital, Philadelphia, PA said “The Histolog technology has the potential to significantly reduce the cost, resources and delays associated with the current lack of real-time high-resolution imaging”. Prof Dr. Douglas Scherr, Clinical Director of Urologic Oncology at the Weill Medical College of Cornell University said “Providing imaging data at this resolution has the potential to aid in patient care. In our practice and across Urology, as a field, we are facing limitations in the ability to provide timely decisions to our patients. We will count on the Histolog Scanner to provide us with the ability to image the tissues’ microstructures in real-time and to enable us to make immediate decisions.”

The FDA clearance of the Histolog® Scanner marks a crucial moment in SamanTree Medical’s mission to expand its innovative imaging solutions globally. With this clearance, SamanTree is set to accelerate its U.S. market entry, ensuring that more healthcare providers can leverage the benefits of this cutting-edge technology.

About SamanTree Medical

SamanTree Medical is committed to enhancing clinical outcomes through the development of advanced imaging technologies. The Histolog® Scanner, now FDA-cleared, offers realtime, high-resolution imaging of excised tissue surfaces, providing physicians with this information for immediate assessments. Following the initial commercialization in Europe, the Histolog® Scanner is poised to make a significant impact in the U.S. healthcare market.

For more information, visit www.samantree.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240912995435/en/

Contacts

Contact Information
Olivier Delporte
CEO, SamanTree Medical
info@samantree.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BRUNO to Showcase Acclaimed Lifestyle and Travel Collections at Ambiente 20262.2.2026 10:00:00 EET | Press release

Tokyo-based lifestyle company BRUNO, Inc. (Headquarters: Shinjuku-ku, Tokyo; President & CEO: Tetsu Shiota), dedicated to the planning, development, and sale of lifestyle products, is pleased to announce its participation in Ambiente—the world’s leading international consumer goods trade fair held in Frankfurt, Germany. The company will showcase its two flagship brands: "BRUNO," a lifestyle brand dedicated to "enjoying life to the fullest," and "MILESTO," a premium travel brand designed for those who "live every day like a journey." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202663769/en/ Our participation in Ambiente marks a pivotal step in our global expansion strategy, as outlined in our current medium-term management plan. We are excited to introduce BRUNO and MILESTO—brands that have earned immense loyalty in Japan—to a global audience. Our exhibit showcases a curated selection of flagship products and latest inn

Reges Elektrik Acquires the Demirli Wind Power Plant, One of Türkiye ’ s Most Significant Wind Energy Projects2.2.2026 10:00:00 EET | Press release

Reges Elektrik, a dynamic and innovative leader in the Turkish energy sector, has announced the acquisition of Tuşpa Enerji Üretim A.Ş. as part of its strategic growth roadmap. Through this landmark acquisition, Reges Elektrik will launch electricity production at the 70 MW Demirli Wind Power Project, located in the Kaman district of Kırşehir. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126059611/en/ From left to right: Enver Altuncu, General Manager and Board Member at Reges Elektrik; Cansu Ünal Öngören, CFO and Board Member at Reges Elektrik; Geert Dooms, General Manager at RES Türkiye; Kağan Gilik, Deputy General Manager at RES Türkiye. Acquired from RES Türkiye, a subsidiary of RES Group—the world’s largest independent renewable energy company—the Demirli Project represents a pivotal milestone in Reges Elektrik’s decisive expansion into energy production. With this investment, the company scales its operations to i

Teledyne FLIR Defense Wins $17.5 Million Contract from armasuisse to Deliver Black Hornet 4 Nano-Drones for Dismounted and Vehicle-Integrated Reconnaissance2.2.2026 09:00:00 EET | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), announced that it has received a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne dismountable Intelligence, Surveillance, and Reconnaissance (ISR) capability sensor for armasuisse’s Piranha 8x8 Armored engineering vehicle program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201061637/en/ Teledyne FLIR Defense has won a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne capability sensor for armasui

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 08:00:00 EET | Press release

Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation aesthetic solutions that address evolving needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201157212/en/ “We pioneered the development of RelabotulinumtoxinA to address the growing demand for faster-acting and longer-lasting anti-wrinkle solutions. We’re excited about the potential to bring this innovative neuromodulator to the U.S., offering advanced performance and ease of use and building on our portfolio of neuromodulators that meets the full spectrum of injecto

High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 09:00:00 EET | Press release

Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye